Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras

Selective degradation of proteins by proteolysis targeting chimeras (PROTACs) offers a promising potential alternative to protein inhibition for therapeutic intervention. Current PROTAC molecules incorporate a ligand for the target protein, a linker, and an E3 ubiquitin ligase recruiting group, which bring together target protein and ubiquitinating machinery. Such hetero-bifunctional molecules require significant linker optimization and possess high molecular weight, which can limit cellular permeation, solubility, and other drug-like properties. We show here that the hetero-bifunctional molecule can be formed intracellularly by bio-orthogonal click combination of two smaller precursors. We designed a tetrazine tagged thalidomide derivative which reacts rapidly with a trans-cyclo-octene tagged ligand of the target protein in cells to form a cereblon E3 ligase recruiting PROTAC molecule. The in-cell click-formed proteolysis targeting chimeras (CLIPTACs) were successfully used to degrade two key oncology targets, BRD4 and ERK1/2. ERK1/2 degradation was achieved using a CLIPTAC based on a covalent inhibitor. We expect this approach to be readily extendable to other inhibitor-protein systems because the tagged E3 ligase recruiter is capable of undergoing the click reaction with a suitably tagged ligand of any protein of interest to elicit its degradation.

[1]  R. Weissleder,et al.  Bioorthogonal Small‐Molecule Ligands for PARP1 Imaging in Living Cells , 2010, Chembiochem : a European journal of chemical biology.

[2]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[3]  Jennifer A. Prescher,et al.  Finding the right (bioorthogonal) chemistry. , 2014, ACS chemical biology.

[4]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[5]  F. Holding,et al.  In-gel activity-based protein profiling of a clickable covalent ERK1/2 inhibitor. , 2016, Molecular bioSystems.

[6]  R. Deshaies Protein degradation: Prime time for PROTACs. , 2015, Nature chemical biology.

[7]  J. English,et al.  Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase. , 2014, Journal of medicinal chemistry.

[8]  A. Windhorst,et al.  A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging. , 2016, ACS medicinal chemistry letters.

[9]  R. Roskoski ERK1/2 MAP kinases: structure, function, and regulation. , 2012, Pharmacological research.

[10]  C. Crews,et al.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.

[11]  Karen Roberts,et al.  Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. , 2015, Journal of medicinal chemistry.

[12]  J. Fox,et al.  trans-Cyclooctene--a stable, voracious dienophile for bioorthogonal labeling. , 2013, Current opinion in chemical biology.

[13]  E. Choi,et al.  Impact of linker length on the activity of PROTACs. , 2011, Molecular bioSystems.

[14]  Michael A. Koldobskiy,et al.  Chemical genetic control of protein levels: selective in vivo targeted degradation. , 2004, Journal of the American Chemical Society.

[15]  C. Crews,et al.  Small-Molecule PROTACS: New Approaches to Protein Degradation. , 2016, Angewandte Chemie.

[16]  Joseph M. Fox,et al.  Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. , 2008, Journal of the American Chemical Society.

[17]  P. Crespo,et al.  Working Without Kinase Activity: Phosphotransfer-Independent Functions of Extracellular Signal–Regulated Kinases , 2011, Science Signaling.

[18]  J. Blake,et al.  Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2. , 2015, Journal of medicinal chemistry.

[19]  I. E. Smith,et al.  Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.

[20]  R. Jain,et al.  Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase. , 2015, Bioorganic & medicinal chemistry letters.

[21]  S. Baek,et al.  Use of PROTACS as molecular probes of angiogenesis. , 2005, Bioorganic & medicinal chemistry letters.

[22]  R. Weissleder,et al.  Bioorthogonal imaging of aurora kinase A in live cells. , 2012, Angewandte Chemie.

[23]  Jason W. Chin,et al.  Selective, rapid and optically switchable regulation of protein function in live mammalian cells. , 2015, Nature chemistry.

[24]  A. Ciulli,et al.  Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.

[25]  Eunhwa Ko,et al.  Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. , 2016, Angewandte Chemie.

[26]  James E. Bradner,et al.  Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.

[27]  Lihua Liu,et al.  ChromoHub: a data hub for navigators of chromatin-mediated signalling , 2012, Bioinform..

[28]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Pedro Soares,et al.  Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities , 2014, Journal of medicinal chemistry.

[30]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[31]  Jeremy L. Jenkins,et al.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.

[32]  T. Corson,et al.  Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One. , 2008, ACS chemical biology.